secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2026-08-18T23:56:38+00:00
Accession:  0001628280-26-057804
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience receives Nasdaq delisting notice for negative stockholders' equity
--------------------------------------------------------------------------------

- Stockholders' equity was ($497,307) as of June 30, 2026, below Nasdaq's $2.5M minimum requirement.
- Company has until Oct 2, 2026 to submit a compliance plan; Nasdaq may grant extension to Feb 14, 2027.
- Common stock continues trading on Nasdaq under 'SKYE'; no immediate effect on listing.
- Company evaluating alternatives to regain compliance; no assurance of success.
- Also disclosed proposed acquisition of Redx Pharma Limited (Transaction Agreement dated Aug 14, 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026057804/0001628280-26-057804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026057804/skye-20260818.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-057804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer